全身化疗联合肝动脉栓塞化疗治疗乳腺癌术后肝转移的临床疗效观察

Clinical observation of breast cancer liver metastasis after mastectomy by combined treatment of transarterial chemoembolization (TACE) and systemic chemotherapy

目的:探讨全身化疗联合肝动脉栓塞化疗治疗乳腺癌术后肝转移的临床疗效及毒副反应。方法:对62例乳腺癌患者分别采用全身化疗或全身化疗联合肝动脉栓塞化疗,比较其疗效。结果:62例患者中总有效率(OR)为51.6%,其中,全身化疗组的客观有效率(RR)为37.0%,全身化疗加肝动脉栓塞化疗的患者客观有效率(RR)为62.9%,联合治疗组的疗效明显好于单纯化疗组(P<0.05)。总中位生存期为17个月,其中,全身化疗组中位生存期为15个月,全身化疗加TACE组中位生存期为22个月,两者的生存期有显著差异(P<0.05)。主要毒副反应为骨髓抑制和胃肠道反应。结论:全身化疗联合肝动脉栓塞化疗治疗乳腺癌肝转移疗效显著,毒副作用小,可以作为乳腺癌肝转移综合治疗中的主要治疗手段。

Objective：To investigate the efficacy and toxicity of combined treatment of transarterial chemoembolization （TACE） and systemic chemotherapy for breast cancer liver metastasis after mastectomy.Methods：All 62 cases of metastatic breast cancer were treated by systemic chemotherapy or combined systemic chemotherapy with TACE.Results：Of the 62 patients,the overall response rate （OR） was 51.6％,including 37.0％ in chemotherapy group,and 62.9％ in systemic chemotherapy plus TACE group.Combined treatment group was better than that of the systemic chemotherapy （P ＜ O.05）.The total median overall survival （mOS）was 17 months and of which 15 months in systemic chemotherapy group and 22 months in systemic chemotherapy plus TACE group.There was significant diference between systemic chemotherapy group and systemic chemotherapy plus TACE group （P ＜ 0.05）.The main treatment-related adverse events were bone marrow inhibition and enterogastric reaction.Conclusion：Combined treatment of systemic chemotherapy and TACE is an effective and feasible therapy for breast cancer liver metastasis after mastectomy.The toxicity profile was acceptable.